市場調查報告書
商品編碼
1145973

深部腦刺激 (DBS) 設備市場 - 增長、趨勢、COVID-19 影響和預測(2022-2027 年)

Deep Brain Stimulation Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

深部腦刺激 (DBS) 設備市場預計在預測期內(2022-2027 年)的複合年增長率接近 12.5%。

預計 COVID-19 將對市場增長產生重大影響。根據 2021 年 4 月發表的文章《COVID-19 大流行期間帕金森病的深部腦刺激:患者視角》,患者在 COVID-19 病毒爆發期間尋求深部腦刺激手術的主要原因是:、常規臨床轉診、醫院護理提供的人身安全,嚴重的帕金森病症狀控制不佳。因此,預計在疫情期間,對深部腦刺激的需求增加將推動市場增長。

推動市場增長的關鍵因素是人口迅速老齡化、微創手術日益普及導致神經系統疾病的風險和患病率增加、對設備和技術的需求不斷增加。包括高度先進的深部腦刺激設備的可用性.

深部腦刺激 (DBS) 是一種廣泛用於晚期帕金森病 (PD)、特發性震顫和肌張力障礙的治療方法。然而,在過去的 30 年中,深部腦刺激技術及其擴大的臨床應用取得了巨大的發展。

根據聯合國經濟和社會事務部題為《2020 年世界人口老齡化亮點》的報告,2020 年全球 65 歲及以上的人口將達到 7.27 億。到 2050 年,人口預計將增加一倍以上,達到近 15 億。隨著老年人口的增加,預計神經系統疾病的數量將增加,並有望在不久的將來成為市場的驅動力。

目前,有幾種深部腦刺激療法已獲得歐洲和美國監管機構的批准。美國食品和藥物管理局 (FDA) 已批准波士頓科學公司的 Vercise 深部腦刺激 (DBS) 系統。該系統用於治療帕金森病 (PD) 的症狀。此外,研究人員正在增強現有的 DBS 系統,同時也在開發下一代設備。

研究人員正在使用深部腦刺激來針對大腦的不同區域來研究不同帕金森病人群的治療方法。新系統的幾處修改已經改善了臨床表現。儘管如此,深部腦刺激技術的這些新發展正在鼓勵大量患者社區和醫療保健專業人員。

因此,深部腦刺激技術的每一次進步都應該導致深部腦刺激 (DBS) 設備市場的增長。

主要市場趨勢

在深部腦刺激(DBS)設備市場,帕金森病領域有望佔據主要市場份額

推動這一細分市場增長的主要因素是全球帕金森病患病率不斷上升。一篇題為單胺氧化□ B 抑製劑治療帕金森病的論文發表了過去、現在和未來。根據2022年2月發表的《過去、現在和未來》,全球帕金森病患病率估計約為610萬人,且患病率隨著年齡的增長而增加,達到65歲及以上的1人,估計達到~3人%。此外,根據世界衛生組織(WHO)2021年10月更新的數據,預計到2030年,全球六分之一的人口將超過60歲。

深部腦刺激是帕金森病最常見的手術治療方法。它通常給予患有帕金森病至少 4 年並且從藥物中受益但有運動並發症的人。此外,預計創新產品的推出將在預測期內推動研究部門的增長。例如,2021 年 1 月,美敦力啟動了首創的自適應深部腦刺激 (aDBS) 試驗,以評估自適應深部腦刺激對帕金森病患者的安全性和有效性。此外,深部腦刺激領域的技術進步不斷增加,這推動了整個市場的增長。

預計北美將佔據重要的市場份額,並且預計在預測期內也將保持同樣的態勢

由於腦部疾病的患病率不斷上升,預計北美將在市場上佔據重要份額,並且預計在預測期內也會如此。

根據 2020 年帕金森基金會的數據,美國有近 100 萬人患有帕金森病。其中,據說男性患帕金森病的可能性是女性的 1.5 倍。僅在美國,帕金森病在美國的直接和間接成本(包括治療、殘疾、類似成本以及由於患者無法工作而導致的收入損失)估計為每年 250 億美元。因此,帕金森病對醫療保健系統的負擔日益加重,加上美國經濟形勢的不確定性,促使 OEM(原始設備製造商)開發具有成本效益的設備來治療神經性運動障礙。

2021 年 1 月,波士頓科學 (Boston Scientific) 的一代 vercise Genus 深部腦刺激系統獲得美國食品和藥物管理局的批准,該系統用於治療晚期帕金森病患者的症狀。因此,此類產品的批准和帕金森病發病率的上升正在幫助推動深部腦刺激 (DBS) 設備市場的增長。

競爭格局

由於一些主要市場參與者的存在,深部腦刺激 (DBS) 設備市場正在整合。一些市場參與者包括雅培(St. Jude Medical)、北京 PINS 醫療、波士頓科學公司、Fisher Wallace、Functional Neuromodulation Ltd、Medtronic PLC、NeuroPace Inc 和 Renishaw PLC。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場動態

  • 市場概覽
  • 市場驅動力
    • 人口迅速老齡化導致神經系統疾病的風險和患病率增加
    • 由於微創手術的普及,對設備的需求不斷擴大
    • 技術先進的深部腦刺激 (DBS) 設備的可用性
  • 市場製約因素
    • 與深部腦刺激療法相關的風險
    • 實施對市場產生不利影響的政府政策
  • 波特五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:100 萬美元)

  • 按產品類型
    • 單通道深部腦刺激 (DBS) 設備
    • 雙通道深部腦刺激 (DBS) 設備
  • 按應用
    • 帕金森病
    • 特發性震顫
    • 強迫症
    • 癲癇
    • 肌張力障礙
    • 其他用途
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 神經科診所
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海合會
      • 南非
      • 其他中東和非洲
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第 6 章競爭格局

  • 公司簡介
    • Abbott Laboratories(St. Jude Medical)
    • Beijing PINS Medical Co. Ltd
    • Boston Scientific Corporation
    • Fisher Wallace
    • Functional Neuromodulation Ltd
    • Medtronic PLC
    • NeuroPace Inc.
    • Renishaw PLC

第7章 市場機會今後動向

目錄
Product Code: 64165

The deep brain stimulation devices market is expected to register a CAGR of nearly 12.5% during the forecast period (2022-2027).

COVID-19 is expected to have a significant impact on the growth of the market. According to the article titled 'Deep Brain Stimulation for Parkinson's disease during the COVID-19 pandemic: patient perspective' published in April 2021 the three main reasons given by the patients for seeking deep brain stimulations surgery during the COVID-19 virus outbreak were routine clinical referral, personal safety provided by hospital care and poor control of severe Parkinson's disease symptoms. Thus, the increasing demand for the deep brain stimulation procedure is expected to drive the growth of the market during the pandemic period.

The major factors driving the growth of the market include the rapidly aging population, which is leading to risk and high prevalence of neurological disorders, growing demand for the devices, due to the rising popularity of minimally invasive procedures, and availability of technologically advanced deep brain stimulation devices.

Deep brain stimulation (DBS) is a widely used treatment for advanced Parkinson's disease (PD), essential tremors, and dystonia. However, over the last three decades, in addition to the extension of its clinical applications, there has been tremendous growth in deep brain stimulation technology.

According to the United Nations Department of Economic and Social Affairs report titled 'World Population Ageing 2020 Highlights,' there were 727 million persons aged 65 years or over in the world in 2020. It is expected to become more than double and reach nearly 1.5 billion in 2050. As number of elderly population are projected to increase and this population are more prone to neurological disorders which ultimately drives the market in near future.

Currently, there are multiple deep brain stimulation systems that have been approved by the European and United States regulatory agencies. The United States Food and Drug Administration (FDA) approved Boston Scientific Corporation's Vercise Deep Brain Stimulation (DBS) System. This system is used to treat the symptoms of Parkinson's disease (PD). Additionally, researchers are enhancing their existing DBS systems, while developing the next-generation devices.

The researchers are using deep brain stimulation to target different areas of the brain and studying the treatment in different populations suffering from Parkinson's disease. Some changes in the new systems have shown improvement in clinical outcomes. Nevertheless, these new developments in the deep brain stimulation technology are encouraging a large patient community and healthcare providers.

Hence, all such advancements in the deep brain stimulation technology have to lead to the growth of the deep brain stimulation devices market.

Key Market Trends

Parkinson's Disease Segment is Expected to Hold a Major Market Share in the Deep Brain Stimulation Devices Market

The major factor driving the growth of the segment is the rising global prevalence of Parkinson's disease. According to the article titled ' Monoamine Oxidase-B inhibitors for the treatment of Parkinson's Disease: Past, Present and Future ' published in February 2022 the global prevalence of Parkinson's disease is estimated to be approximately 6.1 million globally, and the prevalence increases with age, reaching 1% to 3% in the population over 65 years of age. In addition, the data updated by World Health Organization (WHO) in October 2021 shows that by 2030, 1 in 6 people in the world will be aged 60 years or over.

Deep brain stimulation is the most commonly performed surgical treatment for Parkinson's disease. It is usually done in people, who have been suffering from Parkinson's disease for at least four years and have benefited from medications but have motor complications. Also, innovative product launches are expected to drive the growth of the studied segment during the forecast period. For instance, in January 2021 Medtronic launched a First-of-its kind Adaptive deep brain stimulation (aDBS) trial for evaluating the safety and efficacy of adaptive deep brain stimulation in patients with Parkinson's disease.Additionally, there is a rising technological advancement in the field of Deep brain stimulation, which is propelling the overall growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant share in the market and expected to do the same in the forecast period due to the increasing prevalence of brain diseases.

According to the Parkinson's Foundation in 2020, nearly one million people in the United States were living with Parkinson's disease. Among these men are 1.5 times more likely to have Parkinson's disease than women. The combined direct and indirect costs of Parkinson's in the United States, including treatment, disability, and similar costs, along with the lost income, owing to the patient's inability to work, are estimated to be valued at USD 25 billion per year in the United States alone. Hence, the growing burden of Parkinson's disease on the healthcare system, coupled with uncertain economic conditions in the United States, has forced the original equipment manufacturers (OEMs) to develop cost-effective devices for the treatment of neurological movement disorders.

In January 2021 Boston Scientific Received Food and Drug Administration approval for the generation vercise Genus deep brain stimulation system which is used to treat symptoms in patients with advanced Parkinsons' disease. Hence, such product approvals and growing incidences of Parkinson's disease have helped in driving the growth of the deep brain stimulation devices market.

Competitive Landscape

The deep brain stimulation devices market is consolidated, owing to the presence of a few major market players. Some of the market players are Abbott Laboratories (St. Jude Medical), Beijing PINS Medical Co. Ltd, Boston Scientific Corporation, Fisher Wallace, Functional Neuromodulation Ltd, Medtronic PLC, NeuroPace Inc., and Renishaw PLC.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapidly Aging Population, Leading to Risk and High Prevalence of Neurological Disorders
    • 4.2.2 Growing Demand for the Devices, Due to Rising Popularity of Minimally Invasive Procedures
    • 4.2.3 Availability of Technologically Advanced Deep Brain Stimulation Devices
  • 4.3 Market Restraints
    • 4.3.1 Risks Associated with Deep Brain Stimulation Procedures
    • 4.3.2 Implementation of Government Policies Negatively Affecting the Market
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Single-channel Deep Brain Stimulator
    • 5.1.2 Dual-channel Deep Brain Stimulator
  • 5.2 By Application
    • 5.2.1 Parkinson's Disease
    • 5.2.2 Essential Tremor
    • 5.2.3 Obsessive Compulsive Disorder
    • 5.2.4 Epilepsy
    • 5.2.5 Dystonia
    • 5.2.6 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Neurological Clinics
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories (St. Jude Medical)
    • 6.1.2 Beijing PINS Medical Co. Ltd
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Fisher Wallace
    • 6.1.5 Functional Neuromodulation Ltd
    • 6.1.6 Medtronic PLC
    • 6.1.7 NeuroPace Inc.
    • 6.1.8 Renishaw PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS